tbuckley/cabot-search huggingface dataset:
How to Make Up for Rotavirus Vaccination Missed During the COVID-19 Pandemic?—Reply
Authors: Malini B. DeSilva, Eric Weintraub, Elyse O. Kharbanda
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
Authors: None YangYang, Xiaohua Gong, Liuqing Yang, Jie Li, Jiaqi Zhang, Lanlan Wei, Guoguo Ye, Yimin Tang, Yujing Jiang, Jianhuan Li, Yuanlong Lin, Fuxiang Wang, Hongzhou Lu, Yingxia Liu
Journal: Journal of Infection (2022)
Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure
Authors: Alvin Chandra, Hicham Skali, Brian Claggett, Scott D. Solomon, Joseph S. Rossi, Stuart D. Russell, Kunihiro Matsushita, Dalane W. Kitzman, Suma H. Konety, Thomas H. Mosley, Patricia P. Chang, Amil M. Shah
Journal: Journal of the American College of Cardiology (2022)
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Authors: Haichuan Wang, Yi Zhou, Hongwei Xu, Xue Wang, Yi Zhang, Runze Shang, Marie O'Farrell, Stephanie Roessler, Carsten Sticht, Andreas Stahl, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen
Journal: Hepatology (2022)

Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a FASN inhibitor, either alone or in combination, for HCC treatment.The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-programmed death ligand 1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models. RNA sequencing was performed to elucidate the effects of TVB3664 on global gene expression and tumor metabolism. TVB3664 significantly ameliorated the fatty liver phenotype in the aged mice and AKT-induced hepatic steatosis. TVB3664 monotherapy showed moderate efficacy in NASH-related murine HCCs, induced by loss of phosphatase and tensin homolog and MET proto-oncogene, receptor tyrosine kinase (c-MET) overexpression. TVB3664, in combination with cabozantinib, triggered tumor regression in this murine model but did not improve the responsiveness to immunotherapy. Global gene expression revealed that TVB3664 predominantly modulated metabolic processes, whereas TVB3664 synergized with cabozantinib to down-regulate multiple cancer-related pathways, especially the AKT/mammalian target of rapamycin pathway and cell proliferation genes. TVB3664 also improved the therapeutic efficacy of sorafenib and cabozantinib in the FASN-dependent c-MYC-driven HCC model. However, TVB3664 had no efficacy nor synergistic effects in FASN-independent murine HCC models.This preclinical study suggests the limited efficacy of targeting FASN as monotherapy for HCC treatment. However, FASN inhibitors could be combined with other drugs for improved effectiveness. These combination therapies could be developed based on the driver oncogenes, supporting precision medicine approaches for HCC treatment.
Translatability Analysis of National Institutes of Health–Funded Biomedical Research That Applies Artificial Intelligence
Authors: Feyisope R. Eweje, Suzie Byun, Rajat Chandra, Fengling Hu, Ihab Kamel, Paul Zhang, Zhicheng Jiao, Harrison X. Bai
Journal: JAMA Network Open (2022)

Despite the rapid growth of interest and diversity in applications of artificial intelligence (AI) to biomedical research, there are limited objective ways to characterize the potential for use of AI in clinical practice.To examine what types of medical AI have the greatest estimated translational impact (ie, ability to lead to development that has measurable value for human health) potential.In this cohort study, research grants related to AI awarded between January 1, 1985, and December 31, 2020, were identified from a National Institutes of Health (NIH) award database. The text content for each award was entered into a Natural Language Processing (NLP) clustering algorithm. An NIH database was also used to extract citation data, including the number of citations and approximate potential to translate (APT) score for published articles associated with the granted awards to create proxies for translatability.Unsupervised assignment of AI-related research awards to application topics using NLP.Annualized citations per $1 million funding (ACOF) and average APT score for award-associated articles, grouped by application topic. The APT score is a machine-learning based metric created by the NIH Office of Portfolio Analysis that quantifies the likelihood of future citation by a clinical article.A total of 16 629 NIH awards related to AI were included in the analysis, and 75 applications of AI were identified. Total annual funding for AI grew from $17.4 million in 1985 to $1.43 billion in 2020. By average APT, interpersonal communication technologies (0.488; 95% CI, 0.472-0.504) and population genetics (0.463; 95% CI, 0.453-0.472) had the highest translatability; environmental health (ACOF, 1038) and applications focused on the electronic health record (ACOF, 489) also had high translatability. The category of applications related to biochemical analysis was found to have low translatability by both metrics (average APT, 0.393; 95% CI, 0.388-0.398; ACOF, 246).Based on this study's findings, data on grants from the NIH can apparently be used to identify and characterize medical applications of AI to understand changes in academic productivity, funding support, and potential for translational impact. This method may be extended to characterize other research domains.
TCT-3 Pretreatment with P2Y12 receptor antagonists is not associated with improved patency of infarct related-artery in STEMI – A report from SCAAR
Authors: Christian Dworeck, Inger Haraldsson, Oscar Angeras, Jacob Odenstedt, Dan Ioanes, Petur Petursson, Sebastian Volz, Per Albertsson, Jonas Persson, Sasha Koul, Björn Redfors, David Erlinge, Truls Råmunddal, Elmir Omerovic
Journal: Journal of the American College of Cardiology (2016)
Updated USPSTF Guidelines for Screening for Atrial Fibrillation
Authors: Rod Passman, Ben Freedman
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands
Authors: Daniel Kwon, Katsuyoshi Takata, Zhengxing Zhang, Lauren Chong, Bryan Fraser, Jutta Zeisler, Tomoko Miyata-Takata, Helen Merkens, Julie Rousseau, Tomohiro Aoki, Hsiou-Ting Kuo, Ruiyan Tan, Chengcheng Zhang, Joseph Lau, Diego Villa, Carlos F. Uribe, Kuo-Shyan Lin, Christian Steidl, Francois Benard
Journal: Clinical Cancer Research (2022)

Mantle cell lymphoma (MCL) is associated with poor survival. The purpose of this study was to assess whether the C-X-C chemokine receptor type 4 (CXCR4) is a useful target for imaging and radioligand therapy of MCL, using a novel pair of radioligands, [68Ga]Ga and [177Lu]Lu-BL02.We performed a retrospective analysis of 146 patients with MCL to evaluate CXCR4 expression and its correlation with outcomes. Guided by in silico methods, we designed BL02, a new radioligand labelled with 68Ga or 177Lu for PET imaging and therapy, respectively. We performed imaging and biodistribution studies in xenograft models with varying CXCR4 expression. We evaluated [177Lu]Lu-BL02 in MCL models, and evaluated its potential for therapy in Z138 MCL xenografts.Phosphorylated and nonphosphorylated CXCR4 expression were correlated with poor survival in patients with MCL and characterized by unique underlying molecular signatures. [68Ga]Ga-BL02 uptake correlated with CXCR4 expression, and localized lesions in a metastatic xenograft model. [177Lu]Lu-BL02 showed high uptake in MCL xenografts. Therapy studies with a single dose in the Z138 model showed tumor regression and improved survival compared with a control group. Upon regrowth, the treated mice experienced concurrent metastasis alongside localized xenograft regrowth, and recurrent lesions showed enhanced CXCR4 signaling.CXCR4 is an independent factor of poor prognosis for MCL and a promising target for imaging and radioligand therapy. [68Ga]Ga-BL02 showed high contrast to visualize CXCR4-expressing xenografts for PET imaging and [177Lu]Lu-BL02 induced rapid tumor regression in a preclinical model of MCL.
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis
Authors: Xiao‐Dong Mo, Shen‐Da Hong, Yan‐Li Zhao, Er‐Lie Jiang, Jing Chen, Yang Xu, Zi‐Min Sun, Wei‐Jie Zhang, Qi‐Fa Liu, Dai‐Hong Liu, Ding‐Ming Wan, Wen‐Jian Mo, Han‐Yun Ren, Ting Yang, He Huang, Xi Zhang, Xiao‐Ning Wang, Xian‐Min Song, Su‐Jun Gao, Xin Wang, Yi Chen, Bing Xu, Ming Jiang, Xiao‐Bing Huang, Xin Li, Hong‐Yu Zhang, Hong‐Tao Wang, Zhao Wang, Ting Niu, Ji‐Shi Wang, Ling‐Hui Xia, Xiao‐Dan Liu, Fei Li, Fang Zhou, Tao Lang, Jiong Hu, Sui‐Jing Wu, Xiao‐Jun Huang
Journal: American Journal of Hematology (2022)

Abstract Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR‐aGVHD patients treated with basiliximab in a real‐world setting. Nine hundred and forty SR‐aGVHD patients were recruited from 36 hospitals in China, and 3683 doses of basiliximab were administered. Basiliximab was used as monotherapy ( n = 642) or in combination with other second‐line treatments ( n = 298). The cumulative incidence of overall response rate (ORR) at day 28 after basiliximab treatment was 79.4% (95% confidence interval [CI] 76.5%–82.3%). The probabilities of nonrelapse mortality and overall survival at 3 years after basiliximab treatment were 26.8% (95% CI 24.0%–29.6%) and 64.3% (95% CI 61.2%–67.4%), respectively. A 1:1 propensity score matching was performed to compare the efficacy and safety between the monotherapy and combined therapy groups. Combined therapy did not increase the ORR; conversely, it increased the infection rates compared with monotherapy. The multivariate analysis showed that combined therapy, grade III–IV aGVHD, and high‐risk refined Minnesota aGVHD risk score before basiliximab treatment were independently associated with the therapeutic response. Hence, we created a prognostic scoring system that could predict the risk of having a decreased likelihood of response after basiliximab treatment. Machine learning was used to develop a protocol that maximized the efficacy of basiliximab while maintaining acceptable levels of infection risk. Thus, real‐world data suggest that basiliximab is safe and effective for treating SR‐aGVHD.
TCTAP A-025 Predictors of Mortality in Acute Myocardial Infarction Patients with Unprotected Left Main Coronary Artery Disease
Authors: Sung Hun Park, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Li Hu, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Correction:<i>Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma</i>
Authors: Jerome Galon, Luciana Batista, Florence Marliot, Jacques Fieschi, Marc Van den Eynde, Franck Pagès, Fabienne Hermitte, Xiaoyi Chen, Amos Kirilovsky, Thomas Sbarrato, Carine El Sissy, Nacilla Haicheur-Adjouri, Maria-Gabriela Anitei, Ana-Maria Musina, Viorel Scripcariu, Christine Lagorce-Pagès
Journal: Journal for ImmunoTherapy of Cancer (2020)
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
Authors: Noelia Purroy, Yuzhou Evelyn Tong, Camilla K. Lemvigh, Nicoletta Cieri, Shuqiang Li, Erin M. Parry, Wandi Zhang, Laura Z. Rassenti, Thomas J. Kipps, Susan L. Slager, Neil E. Kay, Connie Lesnick, Tait D. Shanafelt, Paolo Ghia, Lydia Scarfò, Kenneth J. Livak, Peter V. Kharchenko, Donna S. Neuberg, Lars Rønn Olsen, Jean Fan, Satyen H. Gohil, Catherine J. Wu
Journal: Blood (2022)
Perspectives About Emergency Department Care Encounters Among Adults With Opioid Use Disorder
Authors: Kathryn Hawk, Ryan McCormack, E. Jennifer Edelman, Edouard Coupet, Nicolle Toledo, Phoebe Gauthier, John Rotrosen, Marek Chawarski, Shara Martel, Patricia Owens, Michael V. Pantalon, Patrick O’Connor, Lauren K. Whiteside, Ethan Cowan, Lynne D. Richardson, Michael S. Lyons, Richard Rothman, Lisa Marsch, David A. Fiellin, Gail D’Onofrio
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Emergency departments (EDs) are increasingly initiating treatment for patients with untreated opioid use disorder (OUD) and linking them to ongoing addiction care. To our knowledge, patient perspectives related to their ED visit have not been characterized and may influence their access to and interest in OUD treatment. <h3>Objective</h3> To assess the experiences and perspectives regarding ED-initiated health care and OUD treatment among US patients with untreated OUD seen in the ED. <h3>Design, Setting, and Participants</h3> This qualitative study, conducted as part of 2 studies (Project ED Health and ED-CONNECT), included individuals with untreated OUD who were recruited during an ED visit in EDs at 4 urban academic centers, 1 public safety net hospital, and 1 rural critical access hospital in 5 disparate US regions. Focus groups were conducted between June 2018 and January 2019. <h3>Main Outcomes and Measures</h3> Data collection and thematic analysis were grounded in the Promoting Action on Research Implementation in Health Services (PARIHS) implementation science framework with evidence (perspectives on ED care), context (ED), and facilitation (what is needed to promote change) elements. <h3>Results</h3> A total of 31 individuals (mean [SD] age, 43.4 [11.0] years) participated in 6 focus groups. Twenty participants (64.5%) identified as male and most 13 (41.9%) as White; 17 (54.8%) reported being unemployed. Themes related to evidence included patients’ experience of stigma and perceived minimization of their pain and medical problems by ED staff. Themes about context included the ED not being seen as a source of OUD treatment initiation and patient readiness to initiate treatment being multifaceted, time sensitive, and related to internal and external patient factors. Themes related to facilitation of improved care of patients with OUD seen in the ED included a need for on-demand treatment and ED staff training. <h3>Conclusions and Relevance</h3> In this qualitative study, patients with OUD reported feeling stigmatized and minimized when accessing care in the ED and identified several opportunities to improve care. The findings suggest that strategies to address stigma, acknowledge and treat pain, and provide ED staff training should be implemented to improve ED care for patients with OUD and enhance access to life-saving treatment.
Selecting the best candidates for platinum-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients
Authors: L. Afferi, C. Lonati, F. Montorsi, A. Briganti, A. Mari, G.B. Schulz, P. Black, E. Di Trapani, R.J. Karnes, M.C. Mir, M. Rink, S. Zamboni, A. Antonelli, A. Tafuri, W. Krajewski, E. Xylinas, F. Soria, J.Y. Teoh, A. Mattei, S. Albisinni, F. Roghmann, M. Alvarez-Maestro, S.F. Shariat, M. Moschini
Journal: European Urology (2021)
Transfer trial: Ancillary study within the UroCCR network. Does the transfer of knowledge from the pioneer generation to the second generation accelerate the learning curve of Robot-Assisted Partial Nephrectomies (RAPN)?
Authors: I. Bentellis, A. Morrone, A. Mellouki, D. Chevallier, N. Doumerc, R. Morgan, F.X. Nouhaud, C. Lecable, J. Long, A. Shaikh, M. Billi, P. Pillot, X. Tillou, J. Bernhard, K. Bensalah, B. Tibi, M. Durand, Y. Ahallal
Journal: European Urology (2021)
National Cancer Database analysis assessing the impact of treatment modalities on survival outcomes in localized neuroendocrine prostate adenocarcinoma
Authors: C. Bronkema, S. Arora, J. Keeley, N. Rakic, A. Sood, D. Dalela, M. Stricker, P. Olson, C.G. Rogers, M. Menon, F. Abdollah
Journal: European Urology (2021)
miR-486 attenuates cardiac ischemia/reperfusion injury and mediates the beneficial effect of exercise for myocardial protection
Authors: Yihua Bei, Dongchao Lu, Christian Bär, Shambhabi Chatterjee, Alessia Costa, Isabelle Riedel, Frank C Mooren, Yujiao Zhu, Zhenzhen Huang, Meng Wei, Meiyu Hu, Sunyi Liu, Pujiao Yu, Kun Wang, Thomas Thum, Junjie Xiao
Journal: Molecular Therapy (2022)

Exercise and its regulated molecules have myocardial protective effects against cardiac ischemia/reperfusion (I/R) injury. The muscle-enriched miR-486 was previously identified to be upregulated in the exercised heart, which prompted us to investigate the functional roles of miR-486 in cardiac I/R injury and to further explore its potential in contributing to exercise-induced protection against I/R injury. Our data showed that miR-486 was significantly downregulated in the heart upon cardiac I/R injury. Both preventive and therapeutic interventions of adeno-associated virus 9 (AAV9)-mediated miR-486 overexpression could reduce cardiac I/R injury. Using AAV9 expressing miR-486 with a cTnT promoter, we further demonstrated that cardiac muscle cell-targeted miR-486 overexpression was also sufficient to protect against cardiac I/R injury. Consistently, miR-486 was downregulated in oxygen-glucose deprivation/reperfusion (OGDR)-stressed cardiomyocytes, while upregulating miR-486 inhibited cardiomyocyte apoptosis through PTEN and FoxO1 inhibition and AKT/mTOR activation. Finally, we observed that miR-486 was necessary for exercise-induced protection against cardiac I/R injury. In conclusion, miR-486 is protective against cardiac I/R injury and myocardial apoptosis through targeting of PTEN and FoxO1 and activation of the AKT/mTOR pathway, and mediates the beneficial effect of exercise for myocardial protection. Increasing miR-486 might be a promising therapeutic strategy for myocardial protection.
Public repository of consultants’ practice details should include competing interests
Authors: Cyril Chantler
Journal: BMJ (2022)

<h3>Objective</h3> To investigate the association between polymyositis (PM)/dermatomyositis (DM) and risks of malignancy. <h3>Methods</h3> We searched Pubmed for articles dated before August 16, 2013. Studies were included if they met the following criteria: (1) a cohort or observational study; (2) PM or DM as one of the exposures of interest; (3) cancer as an outcome of interest; and (4) the rate ratio (RR) or standardized incidence ratio (SIR) were available with their 95% CI. We used random-effects or fixed-effects models to calculate the pooled RR according to the heterogeneity test. <h3>Results</h3> Twenty publications were included. Compared with the general population, the pooled RR for patients with PM, DM, and PM/DM were 1.62 (95% CI 1.19–2.04), 5.50 (4.31–6.70), and 4.07 (3.02–5.12), respectively. The increased risks were more significant in patients within the first year of myositis diagnosis, male patients, and population-based studies (for DM). A significant association was also found between PM or DM and most site-specific malignancies. However, both PM and DM were not associated with stomach and prostate cancers. Significant heterogeneity was found between studies on association between PM/DM and overall malignancy, but not between PM/DM and the majority of site-specific malignancies, suggesting that that inherent malignancy difference may be a major source of heterogeneity. <h3>Conclusion</h3> The present metaanalysis indicates that PM and DM are significantly associated with increased risks of overall malignancy and most site-specific malignancies. The number of studies on association between PM or DM and some malignancies is too small to draw a firm conclusion. Accordingly, more research is needed for these malignancies.